Associated Papers
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Constantinescu SN et al.
Biochemical Society Transactions, 2013
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
Dusa A et al.
Plos One, 2010
Select a paper to view details